Biotest AG (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
41
About the Report
About the Report
Summary
Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary, Spain and in Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.
Biotest AG (BIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Biotest AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10
Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biotest AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12
Biotest Enters Into Research Agreement With EpiVax 13
Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15
Licensing Agreements 16
Affibody Enters into Licensing Agreement with Biotest 16
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18
CEVEC Pharma Enters into Licensing Agreement with Biotest 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
Equity Offering 21
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23
Asset Transactions 24
ADMA Biologics Acquires Certain Assets from Biotest Pharma 24
Acquisition 26
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Biotest AG-Key Competitors 27
Biotest AG-Key Employees 28
Biotest AG-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 32
Strategy And Business Planning 32
Jun 20, 2018: Biotest opens third plasma collection centre in Czech Republic 32
Jan 24, 2018: Biotest opens second plasma collection center in the Czech Republic 33
May 16, 2017: Biotest opens seventh plasma collection center in Hungary 34
Financial Announcements 35
Aug 14, 2018: Biotest sales increase to EUR 200.7 million in the first half of 2018 35
Mar 22, 2018: Biotest reaches 2017 profit guidance 36
Nov 14, 2017: Biotest generates revenues of EUR 377.8 million in the first nine months of 2017 37
May 10, 2017: Biotest will realize EUR 110.5 million in the first quarter of 2017 38
Product News 39
05/03/2018: New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors 39
Other Significant Developments 40
Oct 11, 2017: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Figure
List of Figures
Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Biotest AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biotest AG, Deals By Therapy Area, 2012 to YTD 2018 9
Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10
Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12
Biotest Enters Into Research Agreement With EpiVax 13
Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15
Affibody Enters into Licensing Agreement with Biotest 16
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18
CEVEC Pharma Enters into Licensing Agreement with Biotest 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23
ADMA Biologics Acquires Certain Assets from Biotest Pharma 24
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Biotest AG, Key Competitors 27
Biotest AG, Key Employees 28
Biotest AG, Other Locations 29
Biotest AG, Subsidiaries 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.